AstraZeneca breast cancer combo fails late-stage trial endpoint

AstraZeneca's Etcamah combined with Pfizer's Ibrance missed its primary goal in an advanced breast cancer study, a setback for the drug's development. The failure raises uncertainty over the regimen's regulatory path and competitive positioning. This is a company-specific clinical readout, not a systemic market signal.